



**ACGME International**

**Advanced Specialty Program Requirements for  
Graduate Medical Education in  
Medical Toxicology  
(Emergency Medicine, Preventive Medicine)**

Initial Approval:

1 **ACGME International Specialty Program Requirements for**  
2 **Graduate Medical Education**  
3 **in Medical Toxicology (Emergency Medicine, Preventive Medicine)**  
4

5 **Int. Introduction**  
6

7 *Background and Intent: Programs must achieve and maintain Foundational Accreditation*  
8 *according to the ACGME-I Foundational Requirements prior to receiving Advanced Specialty*  
9 *Accreditation. The Advanced Specialty Requirements noted below complement the ACGME-*  
10 *I Foundational Requirements. For each section, the Advanced Specialty Requirements*  
11 *should be considered together with the Foundational Requirements.*  
12

13 **Int. I. Definition and Scope of the Specialty**  
14

15 Medical toxicology is a clinical specialty that includes the monitoring, prevention,  
16 evaluation, and treatment, in all age groups, of injury and illness due to occupational  
17 and environmental exposures, pharmaceutical agents, and unintentional and  
18 intentional poisoning. A medical toxicology fellowship provides fellows with experience  
19 in the clinical practice of medical toxicology and prepares physicians as practitioners,  
20 educators, researchers, and administrators capable of practicing medical toxicology in  
21 academic and clinical settings.  
22

23 **Int. II. Duration of Education**  
24

25 Int. II.A. The educational program in medical toxicology must be 24 or 36 months in  
26 length.  
27

28 **I. Institution**  
29

30 **I.A. Sponsoring Institution**  
31

32 I.A.1. A fellowship in medical toxicology must function as an integral part of an ACGME-I-  
33 accredited residency in emergency medicine or preventive medicine.  
34

35 **I.B. Participating Sites**  
36

37 I.B.1. Any medical toxicology experience not available at the primary clinical site or  
38 Sponsoring Institution must be provided through an affiliation with a participating  
39 site.  
40

41 I.B.2. Programs using multiple participating sites must ensure the provision of a unified  
42 educational experience for the fellows.  
43

44 I.B.3. The primary clinical site must be a primary hospital or a poison center.  
45

46 I.B.3.a) If the primary clinical site is a poison center, the program must identify a  
47 hospital where the clinical experience will take place.  
48

49 I.B.4. Participating sites, including a poison center, should be in close physical proximity  
50 to the primary clinical site unless they provide special resources that are not  
51 available at the primary clinical site.  
52

53	<b>II.</b>	<b>Program Personnel and Resources</b>	
54			
55	<b>II.A.</b>	<b>Program Director</b>	
56			
57	II.A.1.		The program director must have at least three years of documented educational and/or administrative leadership in an emergency medicine, pediatrics, or preventive medicine residency or in a medical toxicology fellowship.
58			
59			
60			
61	II.A.2.		The program director must have current clinical activity in the practice of medical toxicology.
62			
63			
64	II.A.3.		The program director must have academic involvement in scholarly activity in medical toxicology.
65			
66			
67	<b>II.B.</b>	<b>Faculty</b>	
68			
69	II.B.1.		There must be a minimum of two medical toxicology core physician faculty members based at the primary clinical site, including the program director.
70			
71			
72	II.B.2.		Faculty members must supervise all fellows in their development of clinical, educational, research, advocacy, and administrative skills.
73			
74			
75	II.B.3.		Consultants from appropriate medical specialties must be available for consultation and didactic sessions, to include special expertise in:
76			
77			
78	II.B.3.a)		cardiovascular disease;
79			
80	II.B.3.b)		dermatology;
81			
82	II.B.3.c)		gastroenterology;
83			
84	II.B.3.d)		immunology;
85			
86	II.B.3.e)		nephrology;
87			
88	II.B.3.f)		ophthalmology;
89			
90	II.B.3.g)		pathology;
91			
92	II.B.3.h)		pulmonary disease; and,
93			
94	II.B.3.i)		surgical subspecialties.
95			
96	<b>II.C.</b>	<b>Other Program Personnel</b>	
97			
98	II.C.1.		Consultants from appropriate non-medical specialties must be available for consultation and didactic sessions, to include:
99			
100			
101	II.C.1.a)		biostatistics;
102			
103	II.C.3.b)		botany;
104			

- 105 II.C.3.c) disaster and mass casualty incident management;  
 106  
 107 II.C.3.d) epidemiology;  
 108  
 109 II.C.3.e) environmental toxicology;  
 110  
 111 II.C.3.f) forensic toxicology;  
 112  
 113 II.C.3.g) hazardous materials;  
 114  
 115 II.C.3.h) herpetology;  
 116  
 117 II.C.3.i) industrial hygiene;  
 118  
 119 II.C.3.j) laboratory toxicology;  
 120  
 121 II.C.3.k) mycology;  
 122  
 123 II.C.3.l) occupational toxicology;  
 124  
 125 II.C.3.m) public health; and,  
 126  
 127 II.C.3.n) zoology.

128  
 129 **II.D. Resources**

- 130  
 131 II.D.1. There must be a poison control center or medical toxicology service that  
 132 annually has at least 1,500 encounters from the community that require medial  
 133 toxicologist consultation or intervention.  
 134  
 135 II.D.2. Resources must be available to support the provision of clinical experience in  
 136 adult and pediatric critical care areas.  
 137  
 138 II.D.3. The following must be available at the primary clinical site or at an affiliated  
 139 participating site:  
 140  
 141 II.D.3.b) adult and pediatric inpatient facilities;  
 142  
 143 II.D.3.c) adult and pediatric intensive care facilities;  
 144  
 145 II.D.3.d) adult and pediatric outpatient facilities;  
 146  
 147 II.D.3.e) emergency services for both adult and pediatric patients;  
 148  
 149 II.D.3.f) renal dialysis services with 24-hour availability; and,  
 150  
 151 II.D.3.g) toxicology laboratory services with 24-hour availability.  
 152  
 153 II.D.4. There should be an affiliation with a school of pharmacy or department of  
 154 pharmacology.  
 155  
 156 II.D.4.b) In the absence of an affiliation with a school of pharmacy or department

157 of pharmacy, a Doctor of Pharmacy or PhD pharmacologist should be  
158 appointed to the teaching faculty.

159  
160 II.D.5. There should be an affiliation with a school of public health, department of  
161 health, department of population health, department of community health, or  
162 similar institution to provide regular didactic experience and consultation to  
163 fellows.

164  
165 **III. Fellow Appointment**

166  
167 **III.A. Eligibility Criteria**

168  
169 II.A.1. Prior to appointment in the program, fellows should have completed an ACGME-I-  
170 accredited residency program or a residency program acceptable to the  
171 Sponsoring Institution's Graduate Medical Education Committee.

172  
173 **II.B. Number of Fellows**

174  
175 See International Foundational Requirements, Section III.B.

176  
177 **III. Specialty-Specific Educational Program**

178  
179 **III.A. ACGME-I Competencies**

180  
181 III.A.1. The program must integrate the following ACGME-I Competencies into the  
182 curriculum.

183  
184 III.A.1.a) Professionalism

185  
186 IV.A.1.a).(1) Fellows must demonstrate a commitment to  
187 professionalism and an adherence to ethical principles.

188  
189 IV.A.1.b) Patient Care and Procedural Skills

190  
191 IV.A.1.b).(1) Fellows must provide patient care that is compassionate,  
192 appropriate, and effective for the treatment of health  
193 problems and the promotion of health. Fellows must  
194 demonstrate competence in:

195  
196 IV.A.1.b).(1).(a) gathering accurate, essential information  
197 in a timely manner;

198  
199 IV.A.1.b).(1).(b) integrating information obtained from patient history,  
200 physical examination, physiologic recordings, and test  
201 results to arrive at an accurate assessment and  
202 treatment plan;

203  
204 IV.A.1.b).(1).(c) integrating relevant biological, psychosocial, social,  
205 economic, ethnic, and familial factors into the  
206 evaluation and treatment of their patients;

207  
208 IV.A.1.b).(1).(d) planning and implementing therapeutic treatment,

209		including pharmaceutical, medical device, behavioral, and surgical therapies;
210		
211		
212	IV.A.1.b).(1).(e)	assessing toxicological exposures in occupational evaluations;
213		
214		
215	IV.A.1.b).(1).(f)	serving as the primary or consulting physician responsible for providing direct/bedside patient evaluation, management, screening, and preventive services for toxicology patients;
216		
217		
218		
219		
220	IV.A.1.b).(1).(g)	evaluating and managing patients with acute or chronic workplace occupational and environmental exposures, including responsibility for providing patient and worksite evaluation, management, exposure assessment and control, and preventive services;
221		
222		
223		
224		
225		
226		
227	IV.A.1.b).(1).(h)	evaluating workplace risks and hazards;
228		
229	IV.A.1.b).(1).(i)	managing the entire course of critically poisoned patients broadly representative of society, either as the primary physician or as a consultant;
230		
231		
232		
233	IV.A.1.b).(1).(j)	serving as the primary or consulting physician responsible for providing direct/bedside patient evaluation, management, screening, and preventive services for acutely poisoned patients; and,
234		
235		
236		
237		
238	IV.A.1.b).(1).(k)	consulting on calls from a referral population of poisoned patients under the supervision of a physician who is a medical toxicologist.
239		
240		
241		
242	IV.A.1.b).(5)	Fellows must be able to perform all medical, diagnostic, and surgical procedures considered essential for the area of practice, including demonstrating competence in interpreting the results of diagnostic tests.
243		
244		
245		
246		
247	IV.A.1.c)	Medical Knowledge
248		
249	IV.A.1.c).(1)	Fellows must demonstrate knowledge of established and evolving biomedical clinical, epidemiological, and social-behavioral sciences, as well as the application of this knowledge to patient care. Fellows must demonstrate knowledge of:
250		
251		
252		
253		
254		
255	IV.A.1.c).(1).(a)	major developments in the basic and clinical sciences relating to medical toxicology, through application of this knowledge in the care of their patients;
256		
257		
258		
259	IV.A.1.c).(1).(b)	indications, risks, and limitations for procedures, and management of patients through application of this
260		

261		knowledge in their care;
262		
263	IV.A.1.c).(1).(c)	therapeutic approaches, including resuscitation, initial management, pharmacological basis of antidote use, supportive and other care, and withdrawal syndrome management;
264		
265		
266		
267		
268	IV.A.1.c).(1).(d)	the basic and clinical sciences relating to medical toxicology;
269		
270		
271	IV.A.1.c).(1).(e)	biochemistry of metabolic processes, the pharmacology, pharmacokinetics, teratogenesis, toxicity, and interactions of therapeutic drugs;
272		
273		
274		
275	IV.A.1.c).(1).(f)	biochemistry of toxicants and toxins, kinetics, metabolism, mechanisms of acute and chronic injury, and carcinogenesis;
276		
277		
278		
279	IV.A.1.c).(1).(g)	clinical manifestations and differential diagnosis of poisoning from drugs; industrial, household, environmental, and natural products; and agents of bioterrorism toxicants;
280		
281		
282		
283		
284	IV.A.1.c).(1).(h)	analytical and forensic toxicology, including assay methods and interpretation;
285		
286		
287	IV.A.1.c).(1).(i)	laboratory and other diagnostic assessments, as well as forensics, medicolegal issues, and occupational drug test interpretation;
288		
289		
290		
291	IV.A.1.c).(1).(j)	assessment and population health, including criteria for causal inference, monitoring, occupational assessment and prevention, principles of epidemiology, and statistics;
292		
293		
294		
295	IV.A.1.c).(1).(k)	experimental design and statistical analysis of data as related to laboratory, clinical, and epidemiologic research;
296		
297		
298	IV.A.1.c).(1).(l)	occupational toxicology, including acute and chronic workplace exposure to intoxicants and basic concepts of workplace and industrial hygiene;
299		
300		
301		
302	IV.A.1.c).(1).(m)	prevention of poisoning, including prevention of occupational exposures by intervention methodologies that take into account the epidemiology, environmental factors, and the role of regulation and legislation in prevention;
303		
304		
305		
306		
307		
308	IV.A.1.c).(1).(n)	environmental toxicology, including identification of hazardous materials and the basic principles of management of large-scale environmental contamination and mass exposures;
309		
310		
311		
312		

313	IV.A.1.c).(1).(o)	function, management, and financing of poison centers;
314		
315	IV.A.1.c).(1).(p)	the role of regional poison centers in response to hazardous materials incidents, including terrorism, risk assessment, and communication;
316		
317		
318		
319	IV.A.1.c).(1).(q)	oral and written communication skills, including risk communication and teaching techniques;
320		
321		
322	IV.A.1.c).(1).(r)	economics of health care and current health care management issues, including cost-effective patient care, quality improvement, resource allocation, and clinical outcomes;
323		
324		
325		
326		
327	IV.A.1.c).(1).(s)	the role of national and international agencies in toxicology; and,
328		
329		
330	IV.A.1.c).(1).(t)	administrative aspects of the practice of medical toxicology.
331		
332		
333	IV.A.1.d)	Practice-Based Learning and Improvement
334		
335	IV.A.1.d).(1)	Fellows must demonstrate the ability to investigate and evaluate their care of patients, to appraise and assimilate scientific evidence, and to continuously improve patient care based on constant self-evaluation and lifelong learning.
336		
337		
338		
339	IV.A.1.e)	Interpersonal and Communication Skills
340		
341	IV.A.1.e).(1)	Fellows must demonstrate interpersonal and communication skills that result in the effective exchange of information and collaboration with patients, patients' families, and health professionals.
342		
343		
344		
345		
346	IV.A.1.f)	Systems-Based Practice
347		
348	IV.A.1.f).(1)	Fellows must demonstrate an awareness of and responsiveness to the larger context and system of health care, including the social determinates of health, as well as the ability to call effectively on other resources in the system to produce optimal care.
349		
350		
351		
352		
353		
354	<b>IV.B.</b>	<b>Regularly Scheduled Educational Activities</b>
355		
356	IV.B.1.	There must be at least four hours per week of planned didactic experiences focused on medical toxicology.
357		
358		
359	IV.B.1.a)	All planned didactic experiences must be supervised by faculty members.
360		
361		
362	IV.B.2.	Fellows must attend required seminars, conferences, and journal clubs.

- 363  
364 IV.B.3. Fellows must actively participate in the planning and delivery of didactic  
365 sessions.  
366
- 367 IV.B.4. The program must ensure that fellows assigned to participating sites will  
368 participate in required conferences and other didactic activities at the primary  
369 clinical site.  
370
- 371 IV.B.4.a) The majority of didactic sessions should take place at the primary  
372 clinical site.  
373
- 374 IV.B.5. Fellows must have instruction in the principles of hyperbaric medicine.  
375
- 376 IV.B.6. Planned didactic experiences should include presentations based on the  
377 defined curriculum and should include morbidity and mortality conferences,  
378 journal review, administrative seminars, and conferences on research methods.  
379
- 380 IV.B.6.a) All planned didactic experiences should have an evaluative component  
381 to measure fellow participation and educational effectiveness, including  
382 faculty-fellow interaction.  
383
- 384 **IV.C. Clinical Experiences**  
385
- 386 IV.C.1. Clinical experiences must be structured to allow fellows to function as a part of  
387 an effective interprofessional team that works together toward the shared goals  
388 of patient safety and quality improvement.  
389
- 390 IV.C.2. Fellows must have a minimum of 12 months in a 24-month program and 18  
391 months in a 36-month program of clinical experience as the primary or consulting  
392 physician responsible for providing direct/bedside patient evaluation,  
393 management, screening, and preventive services.  
394
- 395 IV.C.3. Fellows must have experience with a referral population of poisoned patients  
396 under the supervision of a physician who is a medical toxicologist for the duration  
397 of the program.  
398
- 399 IV.C.4. Fellows must have experience in a local or regional poison center or a regional  
400 referral toxicology service that annually takes at least 1,500 calls requiring  
401 physician telephone consultation or intervention.  
402
- 403 IV.C.4.a) Each fellow must consult on an average of 240 patient encounters per  
404 year through referral calls involving poisoned patients.  
405
- 406 IV.C.5. Fellows without prior experience in adult and pediatric critical care must have  
407 clinical experiences of at least one month in an adult intensive care unit and one  
408 month in a pediatric intensive care unit.  
409
- 410 IV.C.6. Programs must provide fellows with a broad education, including in the basic  
411 skills and knowledge of medical toxicology, so that they may function as  
412 specialists competent in providing comprehensive patient care in medical  
413 toxicology, research, and teaching.  
414

415	IV.C.7.	The curriculum must include the following medical toxicology core content areas:
416		
417	IV.C.7.a)	analytical and forensic toxicology;
418		
419	IV.C.7.b)	assessment and population health;
420		
421	IV.C.7.c)	clinical assessment;
422		
423	IV.C.7.d)	principles of toxicology;
424		
425	IV.C.7.e)	therapeutics; and,
426		
427	IV.C.7.f)	toxins and toxicants.
428		
429	IV.C.8.	Fellows must have patient experience with a heterogeneous clinical spectrum
430		of diagnoses, for patients broadly representative of society in the country or
431		jurisdiction in which the program operates.
432		
433	IV.C.8.a)	Fellows must have patient experiences with diagnoses resulting from
434		patient exposure to:
435		
436	IV.C.8.a).(i)	drugs;
437		
438	IV.C.8.a).(ii)	industrial, household, and environmental toxicants;
439		
440	IV.C.8.a).(iii)	natural products; and,
441		
442	IV.C.8.a).(iv)	other xenobiotics.
443		
444	IV.C.8.b)	Each fellow must evaluate and manage at least 25 patients with acute
445		or chronic workplace occupational and environmental exposures over
446		the course of the educational program.
447		
448	IV.C.8.b).(i)	These patients must be seen in an occupational medicine or
449		toxicology clinic, or as occupational medicine patients in a referral
450		setting.
451		
452	IV.C.8.c)	Each fellow must provide care for at least 200 acutely poisoned patients
453		over the course of the program.
454		
455	IV.C.8.c).(i).	These patients must represent all age groups and populations.
456		
457	IV.C.8.c).(ii)	At least 10 percent of acutely poisoned patients should be
458		children.
459		
460	IV.C.9.	Fellows must have experience in evaluating and managing patients with
461		workplace and environmental exposures and must have experience in workplace
462		evaluation, as well as in an occupational medicine or toxicology clinic.
463		
464	IV.C.10.	Fellows must be provided opportunities to teach and participate in undergraduate,
465		graduate, and continuing education activities.
466		

467	IV.C.11.	Fellows must document required patient care experiences.
468		
469	IV.C.12.	Fellows should have experience in hyperbaric oxygen therapy as available in the
470		country or jurisdiction.
471		
472	<b>IV.C.</b>	<b>Scholarly Activity</b>
473		
474	IV.D.1.	Fellows' Scholarly Activity
475		
476	IV.D.1.a)	The curriculum must advance fellows' knowledge of the basic principles
477		of research, including how research is conducted, evaluated, explained
478		to patients, and applied to patient care.
479		
480	IV.D.1.b)	Fellows must participate in research or scholarly activity that includes at
481		least one of the following:
482		
483	IV.D.1.a).(i)	peer-reviewed funding and research;
484		
485	IV.D.1.a).(ii)	publication of original research or review articles; or,
486		
487	IV.D.1.a).(iii)	presentations at local regional, or national professional and
488		scientific society meetings.
489		
490	IV.D.1. b)	Fellows must complete a scholarly project prior to graduation.
491		
492	IV.D.2.	Faculty Scholarly Activity
493		
494	IV.D.2.a)	All core faculty members must demonstrate significant contributions to
495		the subspecialty of medical toxicology through scholarly activity.
496		
497	IV.D.2.b)	Each core physician faculty member must demonstrate at least one
498		piece of scholarly activity per year, averaged over the past five years.
499		
500	<b>V.</b>	<b>Evaluation</b>
501		
502	<b>V.A.</b>	<b>Fellow Evaluation</b>
503		
504	V.A.1.	Assessment of procedural competence should include a formal evaluation
505		process and not be based solely on a minimum number of procedures
506		performed.
507		
508	<b>V.B.</b>	<b>Clinical Competency Committee</b>
509		
510		See International Foundational Requirements, Section V.B.
511		
512	<b>V.C.</b>	<b>Faculty Evaluation</b>
513		
514		See International Foundational Requirements, Section V.C.
515		
516	<b>V.D.</b>	<b>Program evaluation and Improvement</b>
517		
518		See International Foundational Requirements, Section V.D.

519		
520	<b>V.E.</b>	<b>Program evaluation Committee</b>
521		
522		See International Foundational Requirements, Section V.E.
523		
524	<b>VI.</b>	<b>The Learning and Working Environment</b>
525		
526	<b>VI.A.</b>	<b>Principles</b>
527		
528		See International Foundational Requirements, Section VI.A.
529		
530	<b>VI.B.</b>	<b>Patient Safety</b>
531		
532		See International Foundational Requirements, Section VI.B.
533		
534	<b>VI.C.</b>	<b>Quality Improvement</b>
535		
536		See International Foundational Requirements, Section VI.C.
537		
538	<b>VI.D.</b>	<b>Supervision and Accountability</b>
539		
540	VI.D.1.	The program must have clear guidelines that delineate which Competencies
541		must be met to determine when a fellow can progress to be supervised
542		indirectly.
543		
544	<b>VI.E.</b>	<b>Professionalism</b>
545		
546		See International Foundational Requirements, Section VI.E.
547		
548	<b>VI.F.</b>	<b>Well-Being</b>
549		
550		See International Foundational Requirements, Section VI.F.
551		
552	<b>VI.G.</b>	<b>Fatigue</b>
553		
554		See International Foundational Requirements, Section VI.G.
555		
556	<b>VI.H.</b>	<b>Transitions of Care</b>
557		
558		See International Foundational Requirements, Section VI.H.
559		
560	<b>VI.I.</b>	<b>Clinical Experience and Education</b>
561		
562		See International Foundational Requirements, Section VI.I.
563		
564	<b>VI.J.</b>	<b>On-Call Activities</b>
565		
566		See International Foundational Requirements, Section VI.J.